Both in vivo and in vitro studies have demonstrated that MCP-1 triggers a rich vascular network through M2 macrophages, and targeting TAMs to inhibit MCP-1 reduces angiogenesis and tumor growth in human melanoma xenografts (47). Here, CCL2 is linked to melanoma.